However, the development of better-tolerated agents and the discovery of coincident HDAC inhibitory effects of existing therapies (such as valproate) may offer an alternative route to the development of new treatments that reduce the occurrence of diabetic kidney disease through HDAC inhibition. This evidence concerns the gene HDAC9 and diabetic kidney disease.